Pupillary Dilation Reflex in Healthy Volunteers
Children's National Research Institute · NCT07746167
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–60 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 60
- US sites recruiting
- 1
- Study start
- April 29, 2026
- Record last updated
- August 4, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This a single site, observational study that will examine how the pupil responds to neurostimulation under different conditions in healthy adults. The objective is to measure pupillary dilation reflex (PRD) in response to increasing neurostimulation intensities using the AlgometRx device.
Being studied: No intervention (observational study)
Conditions: Healthy Participants
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 18-60 years.
- In good general health (self-reported).
- Able and willing to provide written informed consent.
Exclusion Criteria
- Eye pathology that prevents accurate pupillometry.
- Pregnancy (Self-Report)
- Diagnosis of autoimmune disorders.
- Diagnosis of any neuropathic disorder
- Inability to complete questionnaires.
Recruiting US locations
Children's National Hospital
Washington D.C., DC 20010
Site contact: Julia Finkel, MD · 202-476-4867 · jfinkel@childrensnational.org
Similar studies in District of Columbia
All healthy volunteers studies in District of Columbia →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Washington D.C., DC + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
International AIDS Vaccine Initiative
- Location
- Washington D.C., DC + 1 other US site
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersPhase 1
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
International AIDS Vaccine Initiative
- Location
- Washington D.C., DC + 2 other US sites
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersEarly Phase 1
Assistance Delivery and Muscle Coordination
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–80